Report copyright - Nivolumab: Largos supervivientes en 2ª línea de cáncer de ......CheckMate 017 & 057: OS (3 years’ minimum follow-up) 0 6 12 18 24 30 36 42 48 54 Δ10% Nivolumab (n = 135) Docetaxel
Please pass captcha verification before submit form